# LifeNet Health's LifeSciences Division to display at BIO International Convention

*New division will introduce biologically relevant research solutions at Booth 1650*

![LifeNet Health logo. (PRNewsFoto/LifeNet Health)](data:None;base64...)

SAN DIEGO, June 19, 2017 /PRNewswire-USNewswire/ -- The recently formed LifeSciences Division of LifeNet Health is exhibiting at this week's BIO International Convention in San Diego (Booth 1650), where it will be introducing its proprietary drug discovery and pre-clinical research solutions.

Established in 2017, the LifeSciences Division is focused on three areas: research tissue, primary cells, and cell biology matrices and services. The net result is a suite of scientific solutions that bring an extraordinary degree of biological precision to the fields of pharmaceutical discovery and pre-clinical testing. These resources are intended for use by pharmaceutical researchers, biotechnology firms and clinical research organizations.

"The standards of quality and innovation that have made us the global standard in allograft surgical solutions also make us uniquely qualified to meet the needs of biomedical research," said Jingsong Chen, MD, General Manager of the LifeSciences Division and LifeNet Health Vice President of Intellectual Property. "Our clinical experience in transplant medicine means we have the expertise to maintain the important biological characteristics in these tissues that will help identify new therapies faster and more efficiently."

Research tissue includes donated organs and tissues that are not suitable for transplantation but that hold the promise of improving lives through scientific discovery. Primary cells are specific, isolated cell types — such as hepatic (liver) cells — that can help speed the process of determining whether new drug treatments are safe for patients. Cell biology includes an array of three-dimensional cellular matrices and services that allow scientists to replicate complex human biology in the laboratory to understand how tumors and organ systems will respond to potential therapies.

The LifeSciences Division is part of the LifeNet Health Institute of Regenerative Medicine, a center of excellence for research and development focused on new applications for innovations derived from donated human tissue.

**About LifeNet Health**LifeNet Health, celebrating 35 years of saving lives, restoring health, and giving hope to thousands each year, is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to [www.LifeNetHealth.org](http://www.lifenethealth.org/).

CONTACT: Dan Shuman, daniel\_shuman@lifenethealth.org, 757-609-4330, office, 757-374-5316, cell